Actinium Pharmaceuticals ATNM

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.05 (-4.39%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Actinium Pharmaceuticals (ATNM)
    Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.14

    • Market Cap

      $35.56 Million

    • Price-Earnings Ratio

      -0.82

    • Total Outstanding Shares

      31.20 Million Shares

    • Total Employees

      49

    • Dividend

      No dividend

    • IPO Date

      July 19, 2007

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      American Stock Exchange

    • Type

      Common Stock

    • Headquarters

      100 park ave., 23rd floor, New york, NY, 10017

    • Homepage

      https://www.actiniumpharma.com

    Historical Stock Splits

    If you bought 30 shares of ATNM before August 11, 2020, you'd have 1 share today.
    Execution DateSplit Amount
    August 11, 20201-for-30 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities, Continuing$30.52 Million
    Net Cash Flow From Operating Activities$-34.81 Million
    Net Cash Flow From Financing Activities$30.52 Million
    Net Cash Flow From Investing Activities$-11,000
    Net Cash Flow, Continuing$-4.31 Million
    Net Cash Flow From Operating Activities, Continuing$-34.81 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Revenues$81,000
    Net Income/Loss Attributable To Parent$-40.91 Million
    Research and Development$33.35 Million
    Basic Average Shares$60.34 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Net Income/Loss Attributable To Noncontrolling Interest$0

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-40.91 Million
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss$-40.91 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Non-current Assets$2.18 Million
    Equity Attributable To Noncontrolling Interest$0
    Current Assets$79.52 Million
    Liabilities$43.91 Million
    Fixed Assets$412,000
    Noncurrent Assets$2.59 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ATNM from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.